title: [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
abstract: Waldenström macroglobulinemia is defined by the presence of monoclonal immunoglobulin IgM type (M-IgM) and evidence of lymphoplasmacytic bone marrow infiltration. The disease has an indolent course, the treatment is only initiated when the disease has begun to damage its carrier. The following symptoms are regarded as proven indications for initiating therapy: B symptoms, symptomatic lymphadenopathy, splenomegaly, anemia with hemoglobin below 100 g / l or thrombocytopenia < 100 × 10(9)/l, caused by lymphoplasmacytic bone marrow infiltration. Frequent indications for initiating treatment include clinical evidence of hyperviscosity or cryoglobulinemia. M-IgM tends to have a character of autoantibody reaching up to 50 %, which may harm the organism, and therefore any proven damage to the organism by an autoimmune activity of M-IgM is also an indication for treatment. The text includes an overview of rare and very rare types of damage to the organism by M-IgM autoimmune activity. A combination of rituximab, cyclophosphamide and dexamethasone (RCD) is recommended for the initial treatment, possibly extended to R-CHOP regimen (rituximab, cyclophosphamide, vincristine, doxorubicin and prednisone). In our cohort of 43 patients the therapy involving a combination of R-CHOP achieved 3 (8.1 %) complete remissions and 31 (83.8 %) partial remissions. The remission in 75 % of the patients lasted more than 3 years. In case of recurrence after > 2 years, the same therapy can be used, in case of a relapse within a shorter period of time different treatment schedules are recommended. High-dose chemotherapy with an autologous transplant of stem cells obtained from peripheral blood is only recommended after the first recurrence for people under 65 years of age without contraindications. The text analyses the benefits of the new drugs for the treatment of Waldenström macroglobulinemia (bendamustine, thalidomide, lenalidomide, ibrutinib and high-dose chemotherapy).
authors.forename: Zdeněk
authors.initials: Z
authors.lastname: Adam
authors.forename: Luděk
authors.initials: L
authors.lastname: Pour
authors.forename: Marta
authors.initials: M
authors.lastname: Krejčí
authors.forename: Sabina
authors.initials: S
authors.lastname: Ševčíková
authors.forename: Eva
authors.initials: E
authors.lastname: Pourová
authors.forename: Eva
authors.initials: E
authors.lastname: Ševčíková
authors.forename: Zdeněk
authors.initials: Z
authors.lastname: Král
authors.forename: Jiří
authors.initials: J
authors.lastname: Mayer
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000740:Anemia / Q000209:etiology; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology; D000077269:Lenalidomide; D008206:Lymphatic Diseases / Q000209:etiology; D009364:Neoplasm Recurrence, Local; D010880:Piperidines; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D011720:Pyrazoles / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012074:Remission Induction; D000069283:Rituximab / Q000008:administration & dosage; D013163:Splenomegaly / Q000209:etiology; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000209:etiology; D014750:Vincristine / Q000627:therapeutic use; D008258:Waldenstrom Macroglobulinemia / Q000150:complications / Q000188:drug therapy* / Q000276:immunology
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007075:Immunoglobulin M; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C571759:R-CHOP protocol; C551803:ibrutinib; D000069283:Rituximab; D013792:Thalidomide; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D000069461:Bendamustine Hydrochloride; D000077269:Lenalidomide; D000225:Adenine; D011241:Prednisone